p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Mohammad KrayemGhanem Ghanem

Abstract

Intrinsic and acquired resistance of metastatic melanoma to (V600E/K)BRAF and/or MEK inhibitors, which is often caused by activation of the PI3K/AKT survival pathway, represents a major clinical challenge. Given that p53 is capable of antagonising PI3K/AKT activation we hypothesised that pharmacological restoration of p53 activity may increase the sensitivity of BRAF-mutant melanoma to MAPK-targeted therapy and eventually delay and/or prevent acquisition of drug resistance. To test this possibility we exposed a panel of vemurafenib-sensitive and resistant (innate and acquired) (V600E/K)BRAF melanomas to a (V600E/K)BRAF inhibitor (vemurafenib) alone or in combination with a direct p53 activator (PRIMA-1(Met)/APR-246). Strikingly, PRIMA-1(Met) synergised with vemurafenib to induce apoptosis and suppress proliferation of (V600E/K)BRAF melanoma cells in vitro and to inhibit tumour growth in vivo. Importantly, this drug combination decreased the viability of both vemurafenib-sensitive and resistant melanoma cells irrespectively of the TP53 status. Notably, p53 reactivation was invariably accompanied by PI3K/AKT pathway inhibition, the activity of which was found as a dominant resistance mechanism to BRAF inhibition in our lines. Fro...Continue Reading

References

Sep 8, 2001·Molecular Cell·V StambolicT W Mak
Mar 5, 2002·Nature Medicine·Vladimir J N BykovGalina Selivanova
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jan 14, 2003·Nature Genetics·Daniele BergamaschiXin Lu
May 5, 2009·Cancer Cell·Jeremy M R LambertVladimir J N Bykov
May 20, 2009·Cell·Jan-Philipp Kruse, Wei Gu
Nov 26, 2009·Nature Reviews. Cancer·Christopher J BrownDavid P Lane
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Dec 15, 2010·Trends in Pharmacological Sciences·Christopher J BrownDavid P Lane
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nikhil WagleLevi A Garraway
Oct 14, 2011·The Journal of Investigative Dermatology·Zhenyu JiHensin Tsao
Jan 20, 2012·The New England Journal of Medicine·Fei SuRichard Marais
Jan 21, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toshio ShimizuAmita Patnaik
Feb 24, 2012·The New England Journal of Medicine·Jeffrey A SosmanAntoni Ribas
Jul 24, 2012·Nature Medicine·Agnieszka GembarskaJean-Christophe Marine
Dec 25, 2012·Nature Cell Biology·Patricia A J Muller, Karen H Vousden
Jul 3, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhenyu JiHensin Tsao
Sep 24, 2013·Lancet·Alexander M M EggermontCaroline Robert
Apr 24, 2014·Apoptosis : an International Journal on Programmed Cell Death·Xin YuDarren R Carpizo

❮ Previous
Next ❯

Citations

May 25, 2016·Expert Review of Anticancer Therapy·Teresa AmaralClaus Garbe
Oct 26, 2016·Advances in Biological Regulation·James A McCubreyLinda S Steelman
Mar 8, 2017·Journal of Biomolecular Structure & Dynamics·Mahalakshmi RVijayalakshmi Mahadevan
Feb 18, 2017·Genes·Qingyin LuoZunzhen Zhang
Apr 4, 2017·Oncogenesis·G AgaësseI Masse
Sep 16, 2018·Current Oncology Reports·Giuseppe PalmieriUNKNOWN Italian Melanoma Intergroup (IMI)
Dec 16, 2017·Nature Reviews. Cancer·Vladimir J N BykovKlas G Wiman
Oct 17, 2018·Cancer Chemotherapy and Pharmacology·Akshay BinaykeHarish Chander
Sep 12, 2020·Journal for Immunotherapy of Cancer·Alexandra FrazaoAnne Caignard
Dec 9, 2016·Journal of Molecular Cell Biology·Anna de PoloZhi-Min Yuan
Jun 21, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mélanie LambertMarie-Hélène David-Cordonnier
Nov 27, 2020·Frontiers in Oncology·Gaoyang ZhuXuemei Fu
Jul 9, 2021·Apoptosis : an International Journal on Programmed Cell Death·Xiaofeng DaiJianying Zhang
Jul 29, 2021·Molecular Cancer Therapeutics·Kenji M FujiharaNicholas J Clemons

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis